Biogen Inc (BSP:BIIB34)
R$ 169.49 1.36 (0.81%) Market Cap: 149.37 Bil Enterprise Value: 178.06 Bil PE Ratio: 15.80 PB Ratio: 1.56 GF Score: 75/100

Biogen Inc at Leerink CybeRx Series CNS Forum Transcript

Jun 23, 2020 / 04:30PM GMT
Release Date Price: R$232.82
Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst

All right. Good afternoon, everybody. Welcome back. We are lucky enough for our next session to have Chris Henderson, who is the Head of Research at a little company called Biogen. And Chris, you've been in this new role now since March, but you have been in this organization for almost 6 years.

Questions & Answers

Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst

So maybe you could just give us just a sense of behind the scenes at Biogen, talk about the general strategy of R&D there, your research capabilities, the R&D mantra, how maybe you're even different from a few other organizations, just quickly just set the stage?

Christopher Henderson
Biogen Inc. - VP & Head of Neuromuscular & Movement Disorders Research Unit

Yes, I think that's a really good way to start, actually, because I think our main mantra is what separates us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot